On a full year basis, 2008 revenues were $134.1 million, a decline of 4.7%, compared to $140.7 million in 2007. The 2007 revenue included approximately $11.2 million of non-recurring microfluidics license and contract revenues, which were partially offset in 2008 by strong growth of Caliper's imaging and research products for genomics applications.
Net loss for the full year was $68.3 million ($1.42 per share), which includes $48.0 million ($1.00 per share) of non-cash goodwill impairment and other restructuring charges. This compares to a net loss of $24.1 million ($0.51 per share) in 2007. Non-GAAP net loss per share for 2008 was $0.27 compared to a net loss per share of $0.25 in 2007.
Fourth Quarter Highlights:
|SOURCE Caliper Life Sciences, Inc.|
Copyright©2009 PR Newswire.
All rights reserved